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Aside from clinical endpoints like height gain, health-related quality of life has also become
an important outcome indicator in the medical field. However, the data on short stature
and health-related quality of life is inconsistent. Therefore, we examined changes in
health-related quality of life in German children with idiopathic growth hormone deficiency
or children born small for gestational age before and after 12 months of human growth
hormone treatment. Children with idiopathic short stature without treatment served as
a comparison group. At baseline, health-related quality of life data of 154 patients
with idiopathic growth hormone deficiency (n = 65), born small for gestational age
(n = 58), and idiopathic short stature (n = 31) and one parent each was collected. Of
these, 130 completed health-related quality of life assessments after 1-year of human
growth hormone treatment. Outcome measures included the Quality of Life in Short
Stature Youth questionnaire, as well as clinical and sociodemographic data. Our results
showed that the physical, social, and emotional health-related quality of life of children
treated with human growth hormone significantly increased, while untreated patients
with idiopathic short stature reported a decrease in these domains. Along with this, a
statistically significant increase in height in the treated group can be observed, while
the slight increase in the untreated group was not significant. In conclusion, the results
showed that human growth hormone treatment may have a positive effect not only on
height but also in improving patient-reported health-related quality of life of children with
idiopathic growth hormone deficiency and children born small for gestational age.
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INTRODUCTION
Short stature is defined as having a height that is lower than two
standard deviation scores below the mean height for age and
gender of the reference population and about 3% of the children
in a population are of small stature (1). It is a common symptom
for a variety of conditions—some of which can be of endocrine
nature such as idiopathic growth hormone deficiency (IGHD).
Although growth hormone deficiency may have congenital or
acquired causes, IGHD may be diagnosed if such deficiency of
growth hormone is found without any apparent cause resulting
in a short statured body (2). However, in most cases, the
pathological cause of short stature in children and adolescents
cannot be determined, which is described as idiopathic short
stature (ISS) (3). Individuals diagnosed with ISS are born normal
sized, but have a low growth velocity and often have a family
history of short stature (4). If infants have a birth weight and/or
length of <2 standard deviation scores they are diagnosed with
small for gestational age (SGA) (3). Without catch-up growth in
the first 2 years these children remain short (5).
Short stature is reported to cause various deficiencies in
physical aspects of daily life and in emotional- and social
well-being (2, 6). Furthermore, chronic psychosocial stress,
stigmatization and social isolation, frequent bullying and less
social competencies than in children who are of normal height
have been reported in short statured children impacting on the
children’s health-related quality of life (HRQOL) (7–9). However,
the data on short stature and HRQOL is inconsistent. Some
studies reported deficits in HRQOL in short statured children
diagnosed with IGHD or SGA (6, 10, 11), others reported no
significant differences from the reference population (12).
The therapeutic options for pediatric endocrinologists to treat
short children with human growth hormone (hGH) are limited
to a few indications (13–15). Among them are children with
IGHD and SGA, whereas the treatment of short children with
ISS without apparent pathology is not approved by the European
Medicines Agency. The positive effects of hGH treatment such as
inducing catch-up growth and achieving adequate adult height
within the normal range for mid-parental target height have been
shown in children with IGHD inmany studies (16–20). The hGH
treatment of children with SGA leads to a gain in adult height of
7–10 cm and also improves body composition (21–23).
Aside from clinical endpoints like height gain, HRQOL has
also become an important outcome indicator in the medical
field (24). The concept of HRQOL is described as the subjective
perception of health including physical, social and emotional
aspects of well-being (25). Although the use of hGH treatment
in short statured children and adolescents has been shown to
increase height, it is still not clear if this treatment positively
affects the HRQOL of this population. Some studies report
an indirect relationship between height gain and HRQOL in
children with IGHD or SGA and ISS who received hGH
treatment (14, 26, 27), while other studies report inconsistent
findings in differences of HRQOL after hGH treatment (28).
Patients with IDGH or ISS undergoing hGH treatment showed
no differences in HRQOL compared to norm populations (29).
Also Theunissen et al. (12) found no improvement in HRQOL
between treated and untreated children with ISS. Furthermore,
Visser-van Balen et al. (30) showed that hGH treatment did not
improve psychosocial functioning in a small sample of young
adults with ISS or born with SGA compared to an untreated
control group. It is important to consider, that these studies used
amix of various generic and/or short-stature specific instruments
to assess HRQOL and studies were designed differently with
regard to patient samples and control, which makes the
interpretation of results quite challenging. However, the Quality
of Life for Short Statured Youth (QoLISSY) questionnaire is
a disease-specific instrument, designed to assess HRQOL in
children and adolescents with IGHD, SGA or ISS from the
patients’ and parents’ perspective and offers the opportunity to
adequately assess HRQOL in this patient population (31).
Because of the inconsistency in study results andmethodology
concerning HRQOL improvement due to hGH treatment in
short statured children, we raise the research question: Does 1-
year hGH treatment improves HRQOL in children with IGHD
or SGA from the patients’ and parents’ perspective? Therefore,
we conducted a prospective multicenter observational study
in Germany using the disease-specific QoLISSY instrument
to assess the HRQOL of short children with IGHD or SGA
before and 1 year after the start of hGH treatment, taking
gender differences into account. Since hGH treatment of short
children with ISS is not approved in Germany, these untreated
children served as a comparison group. Although reports on
psychosocial outcomes due to hGH treatment are inconsistent,
we hypothesized that HRQOL significantly improves in the
intervention group (children with IGHD or SGA), while no
significant HRQOL changes were expected in the comparison
group (children with ISS).
MATERIALS AND METHODS
Subjects and Procedures
Initially, all German children diagnosed with IGHD or SGA
where hGH treatment was intended were planned to be included
in this observational study. Thus, all children hospitals and
pediatric endocrinologist across Germany were informed about
the study. However, due to lacking endorsement of the clinicians,
only 11 pediatric endocrinologists from 9 children hospitals and
2 medical practices in Germany agreed to recruit patients for the
study. Between 2013 and 2016 the patients were consecutively
recruited at initial visits at a pediatric endocrinologist. The
participating clinicians were instructed to inform all newly
admitted patients diagnosed with IGHD, SGA and ISS aged 8–
18 years about the study. With a power of 80% to detect changes
in the QoLISSY Total score (sum of the scales Physical, Social, and
Emotional) and considering dropouts, the desired sample should
include each n = 160 children/adolescents in the intervention
and comparison group and n= 240 parents. If patients agreed to
participate in the study, a written informed consent was obtained
from all patients and their parents/legal guardians. The diagnoses
of IGHD or SGA were made according to current guidelines
(32). The patients in the intervention group were treatment-naïve
and treated with an approved brand of hGH in Germany. Since
children with ISS could not be treated with hGH in Germany,
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short children with the diagnosis of ISS without hGH served as
the comparison group. Patients with any other diagnosis that
result in short stature (e.g., Turner syndrome) and/or displayed
a lack of adequate linguistic competency were not included in
the study.
Children (aged 8–18) and one parent each, as well as parents
of younger children (aged 4–7) from the intervention group,
were asked to complete the pen and paper short stature specific
QoLISSY questionnaire (31) before the start of hGH treatment at
baseline and 1-year after the start of treatment during the waiting
period on-site at the respective clinic or the endocrinologist. The
comparison group of untreated children/adolescents with ISS
also answered the QoLISSY questionnaire at two measurement
points with an equivalent time interval.
In addition to the report on HRQOL as assessed with
the QoLISSY, self-reported socio-demographic data included
patients’ and parents’ sex, date of birth and nationality. Physician-
reported clinical data included diagnosis (ISS, IGHD or SGA),
treatment status and height at time of diagnosis and at time
of assessment.
Since this study was a multicenter study, the study was
approved by the respective ethics committees of the centers,
namely by the Hamburg Medical Chamber, the Saxon medical
chamber, the Hessen medical chamber, the Nordrhein medical
chamber and by the ethics committee of the Friedrich-Alexander
University Erlangen–Nürnberg, of the University of cologne,
of the University Hospital Magdeburg and of the Ludwig-
Maximiliams-University Munich. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
Measures
The QoLISSY questionnaire was developed according to
standardized guidelines, including: (a) focus-groups with item
generation; (b) pilot-test with cognitive debriefing; and (c)
field test with retest (33). The questionnaire for children is
applicable from the age of eight and older, while the parent-
report version is available for parents of children aged 4–18
years. The children’s version (total of 50 items) consists of three
core domains (Physical, Emotion, and Social HRQOL) as well as
three additional domains (Coping, Beliefs, and Treatment). The
parents’ version (total of 66 items) is used to obtain observer
reports on identical domains and assesses additional parent-
specific domains (Future and Effects on parents). Mean QoLISSY
raw scores were computed for each scale when 80% of the data
were available (i.e., missing data lower than 20% of the values for
each scale) and subsequently transformed into a score between
0 and 100, with higher values representing higher HRQOL
(31). The QoLISSY Total score was calculated as the mean of
the three core domain scores (Physical, Social, and Emotional).
Psychometric performance of the QoLISSY questionnaire within
this prospective trial is satisfactory, as recently reported by
Bloemeke et al. (34).
Statistical Analysis
The statistical analyses were performed with the Statistical
Package for the Social Sciences, v.21 (IBM Corp., Armonk, NY),
with the significance level settled at p< 0.05. All assessed data of
the participants was pseudonymized for analysis. Therefore, the
name and other identification characteristics were replaced by an
indication to prevent the identification of the study participant.
Descriptive statistics for socio-demographic and clinical
variables (i.e., mean and SD for continuous variables; frequencies
and percentages for categorical variables) were calculated.
Auxological data (i.e., height) was calculated also in standard
deviation scores (SDS). Reference data for height SDS were
taken from Kromeyer-Hausschild et al. (35) who used the
LMS formula by Cole (36) for calculation. The homogeneity of
sample characteristics across the diagnostic groups at baseline
was examined by independent-samples analysis of variance
(continuous variables) or χ2 tests (categorical variables).
To examine changes in the primary outcome (HRQOL) within
the course of hGH treatment, a repeated measures MANCOVA
for the QoLISSY scales and a repeated measures ANCOVA for
the QoLISSY Total score were conducted. Measurement points
(i.e., baseline vs. 1-year follow-up) were entered as within-
subjects factors, while the treatment status (intervention vs.
comparison group) was entered as between-subjects factor. The
children’s age and time difference between both measurement
points were entered into the models as covariates. Furthermore, a
two-factorial repeated measurement ANCOVA for the QoLISSY
Total score was conducted. Measurement points (i.e., baseline
vs. 1-year follow-up) were entered as the within-subjects factors.
Diagnoses (IGHD, SGA, ISS) and gender, were entered as
between-subjects factors. Children’s age at baseline and time
difference between both measurement points were also entered
in the models as covariates. Pillai’s trace was used as the
test statistic for the MANCOVA/ANCOVA calculations, with
increasing positive values suggesting effects that contribute more
to the model (37). Effect-size measures were presented for
the comparison analyses, with η2p ≥ 0.01, η
2
p ≥ 0.06, and
η
2
p ≥ 0.14 considered as small, medium, and large effects,
respectively (38).
RESULTS
Sample Characteristics
At baseline, 154 patients with diagnosed IGHD (n = 65),
SGA (n = 58), or ISS (n = 31) were assessed (66 QoLISSY
patient-reports from children/adolescents between 8 and 18
years of age and 152 QoLISSY proxy-reports from parents of
4–18 year-old children). Of these, 130 participants, diagnosed
with IGHD (n = 60), SGA (n = 48), or ISS (n = 22),
also completed the QoLISSY questionnaire after 1-year of
hGH treatment (70 patient-reports and 126 parent-reports
at 1-year follow-up), with 24 participants (15.6%) lost to
follow-up because they did not provide HRQOL data after
treatment. Figure 1 provides an overview about the participant
selection. The sociodemographic and clinical characteristics of
participants at baseline and 1-year follow-up are presented
in Table 1. The distribution of children’s sex across the
diagnostic groups was homogeneous at baseline, χ2
(2)
= 5.93,
p = 0.06. However, differences were found on children’s
age, F(2) = 9.21, p < 0.01, with SGA patients being
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FIGURE 1 | Flowchart of participant selection.
significantly younger than children/adolescents with IGHD
or ISS.
Regarding clinical characteristics, a significant difference
between height SDS across the diagnosis groups was found
at baseline, with significant differences between IGHD
(SDS = −2.61) and ISS (SDS = −2.11) as well as between
SGA (SDS = −2.65) and ISS (SDS = −2.11), with patients with
ISS having a statistically higher SDS reaching nearer to a normal
height. Regardless of the treatment status, all patients grew
during the study period. Within the diagnosis groups IGHD and
SGA, there was a significant increase in height SDS and height
(p ≤ 0.01) from baseline to 1-year follow-up. Height gain in
height SDS after 1-year of treatment was M = 0.70 (SD = 0.45)
in patients with IGHD, M = 0.58 (SD = 0.43) in patients with
SGA andM = 0.09 (SD= 0.49) in ISS (Table 1).
HRQOL Before the Start of hGH Treatment
At baseline, t-tests revealed significant differences in
the QoLISSY Total score between the children in the
intervention group (children to be treated) and the
comparison group (children that will remain untreated).
Children in the intervention group rated their HRQOL
significantly lower (M = 51.23, SD = 25.68) before
treatment start, than the comparison children who
remained untreated (M = 64.86, SD = 20.00),
t(−2.23) = 68, p ≤ 0.05. Also in the parent-reports,
parents of children in the intervention group rated the
Total QoL significantly lower (M = 50.31, SD = 23.82)
before treatment start, than parents of children in
the comparison group (M = 61.72, SD = 23.06),
t(−2.49) = 160, p ≤ 0.05.
HRQOL Between Treated and Untreated
Children Within the Course of
hGH Treatment
Patient-Reports
Over the duration of hGH treatment, the repeated measures
MANCOVA for the patient-reported QoLISSY scales revealed
a multivariate significant interaction effect between time and
treatment status, Pillai’s trace = 0.27, F(5,43) = 3.24, p = 0.01,
η
2
p = 0.27 (Table 2). Subsequent univariate analyses (Table 3)
showed that children with IGHD or SGA who were treated with
hGH reported a significant increase in the physical, social, and
emotional HRQOL domain from baseline to 1-year after start
of the treatment, while untreated patients with ISS reported a
decrease in physical, social, and emotional HRQOL over time.
These results were corroborated by the univariate ANCOVA
for repeated measures for the QoLISSY Total score, with a
significant interaction effect between time and treatment status,
F(1,50) = 9.72, p < 0.01, η
2
p = 0.16. This trend held true even
after controlling for the effects of age at baseline, F(1,50) = 0.03,
p= 0.86, η2p = 0.00, and treatment length, F(1,50) = 3.97, p= 0.05,
η
2
p = 0.07 (Figure 2).
Parent-Reports
Regarding the parent-reports, there was a significant multivariate
effect of time, Pillai’s trace = 0.19, F(7,88) = 2.91, p = 0.01,
η
2
p = 0.19. The univariate analyses for the main effect of
time revealed a significant improvement from baseline to 1-
year after start of treatment on the Effects on parents scale,
for both intervention and comparison groups, F(1,94) = 7.75,
p< 0.01, η2p = 0.08.
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TABLE 1 | Sample characteristics and QoLISSY Total scores at baseline and 1-year after human growth hormone treatment.
Baseline (n = 154) 1-year follow-up (n = 130)
IGHD
(n = 65)
SGA
(n = 58)
ISS
(n = 31)
IGHD
(n = 60)
SGA
(n = 48)
ISS
(n = 22)
Sex, n
(%)
Male 48
(73.8%)
33
(56.9%)
16
(51.6%)
44
(73.3%)
29
(60.4%)
11
(50.0%)
Female 17
(26.2%)
25
(43.1%)
15
(48.4%)
16
(26.7%)
19
(39.6%)
11
(50.0%)
Chronological Age
(years), M (SD)
8.09
(3.34)
6.55
(2.64)
9.45
(3.49)
9.22
(3.37)
7.81
(2.76)
10.68
(3.24)
Missing – – – 1
(1.7%)
– –
Age group, n (%) 4–7 years 34
(52.3%)
41
(70.7%)
7
(22.6%)
26
(43.3%)
28
(58.3%)
4
(18.2%)
8–12 years 22
(33.8%)
15
(25.9%)
16
(51.6%)
22
(36.7%)
18
(37.5%)
10
(45.5%)
13–17 years 9
(13.8%)
2
(3.4%)
8
(25.8%)
11
(18.3%)
2
(4.2%)
8
(36.4%)
Missing – – – 1
(1.7%)
– –
Height (cm), M
(SD)
117.11
(17.44)a
108.01
(13.45)a
126.24
(18.86)a
127.04
(17.53)c
118.89
(13.65)c
132.48
(17.77)c
Missing – 1
(1.7%)
1
(3.2%)
2
(3.3%)
2
(4.2%)
1
(4.5%)
Height deviation
(SDS), M (SD)
−2.61
(0.61)b
−2.65
(0.63)b
−2.11
(0.51)b
−1.91
(0.64)d
−2.05
(0.67)d
−2.06
(0.73)d
Missing – 1
(1.7%)
1
(3.2%)
3
(5.0%)
2
(4.2%)
1
(4.5%)
Treatment length
(months), M (SD)
– – – 12.64
(1.93)
12.25
(2.43)
12.73
(2.76)
Missing – – – 1
(1.7%)
– –
QoLISSY Total
scoree, M (SD)
Child report n = 26 n = 15 n = 23 n = 33 n = 18 n = 18
49.48
(27.2)
45.64
(23.3)
64.86
(20.0)
58.90
(24.9)
68.10
(16.6)
60.87
(24.2)
Parent report n = 62 n = 54 n = 31 n = 57 n = 46 n = 22
51.10
(26.3)
48.49
(19.8)
60.20
(23.4)
56.38
(24.6)
58.63
(21.7)
60.62
(25.1)
IGHD, idiopathic growth hormone deficiency; SGA, small for gestational age; ISS, idiopathic short stature; SDS, Standard deviation score; M, Mean; SD, standard deviation.
a Independent-samples analysis of variance: Significant difference between the diagnosis groups in height at T0 (F(2) = 12.74, p ≤ 0.01).
b Independent-samples analysis of variance: Significant difference between the diagnosis groups in height SDS at T0 (F(2) = 8.70, p ≤ 0.01).
c Independent-samples analysis of variance: Significant difference between the diagnosis groups in height at T1 (F(2) = 5.59, p ≤ 0.01).
d Independent-samples analysis of variance: No significant difference between the diagnosis groups in height SDS at T1 (F(2) = 7.21, p = 0.48).
eSum of the scales Physical, Social, Emotional.
Nomultivariate effects of treatment status, Pillai’s trace= 0.14,
F(7,88) = 2.07, p = 0.06, η
2
p = 0.14, or interaction effects between
time and treatment status, Pillai’s trace = 0.06, F(7,88) = 0.85,
p= 0.55, η2p= 0.06, were found (Table 2). The univariate analyses
for the interaction effect are presented in Table 3.
The ANCOVA for the parent-reported QoLISSY Total
score (Figure 3) showed no significant main effects of time,
F(1,118) = 1.02, p = 0.31, η
2
p = 0.01. Interaction effects between
time and treatment status were also not found when controlling
for age at baseline and treatment length, F(1,118) = 1.33, p= 0.25,
η
2
p = 0.01. However, a significant main effect of treatment
status was found for the parent-reported QoLISSY Total score,
F(1,118) = 5.83, p = 0.02, η
2
p = 0.05, with parents of treated
children reporting lower HRQOL than parents of untreated
children, independently of time of assessment.
HRQOL Between Diagnoses and Gender
Within the Course of hGH Treatment
Patient-Reports
Looking at the total HRQOL differences between diagnoses
and gender, a multifactorial repeated measurement ANCOVA
with age and the time difference between baseline and 1-
year after treatment as covariates revealed a significant main
effect for the interaction between time, diagnose and gender,
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TABLE 2 | Multivariate effects of the repeated measures MANCOVA and effects of the multifactorial repeated measurement ANCOVA.
Report Variables Pillai’s trace F df Error df Sig.
(p-value)
η
2
p
Patient-report Timea 0.17 1.83 5 43 0.12 1.76
Treatment statusa 0.13 1.33 5 43 0.26 1.34
Time* treatment statusa 0.27 3.24 5 43 0.01 0.27
Time* diagnose* genderb 0.14 3.78 2 46 0.03 0.14
Time* diagnose* age groupsb 0.01 0.18 2 46 0.83 0.008
Parent-
report
Timea 0.19 2.91 7 88 0.01 0.14
Treatment statusa 0.14 2.07 7 88 0.06 0.14
Time* treatment statusa 0.06 0.85 7 88 0.55 0.06
Time* diagnose* genderb 0.03 1.81 2 114 0.16 0.03
Time* diagnose* age groupsb 0.06 1.92 4 111 0.11 0.06
aRepeated measures MANCOVA for the QoLISSY scales with children’s age and time difference between both measurement points as covariates.
bTwo-factorial repeated measurement ANCOVA for the QoLISSY Total score with children’s age at baseline and time difference between both measurement points as covariates.
Pillai’s trace = 0.14, F(2,46) = 3.78, p < 0.05, η
2
p = 0.14.
Girls with IGHD and SGA reported an increase in their
HRQOL, which was particularly high in girls born with SGA,
while girls with ISS reported a decrease in their HRQOL.
Boys reported a slight increase in their HRQOL across all
diagnosis groups.
Parent-Reports
In the parent-reports, these results were not statistically
significant (Table 2). Regarding HRQOL differences between
the age groups (4–7 years, 8–12 years, >13 years) over
time, there were no significant interaction effects between
time, age groups and diagnose in patient-reports, nor in the
parent-reports (Table 2).
DISCUSSION
Results of the present study showed that improved growth
of short statured children with IGHD and SGA who were
treated with hGH for 1 year positively affects their short-
term HRQOL compared to untreated short statured children
diagnosed with ISS.
Already at baseline, children with IGHD and SGA who
were about to start treatment were significantly shorter than
patients with ISS. Further, these patients show a statistically
significant lower HRQOL before treatment than children with
ISS. From the children’s point of view, our findings showed a
significant interaction effect between time and treatment status.
Children who were treated with hGH, reported a significant
increase in physical, social, and emotional HRQOL from baseline
to 1-year after treatment, while untreated patients reported
a decrease in physical, social, and emotional HRQOL over
time. The total HRQOL differences between the diagnoses and
the gender revealed a significant interaction effect between
time, diagnosis and gender. Treated girls with IGHD or SGA
reported an increase in their HRQOL, while girls diagnosed
with ISS from the comparison group, reported a decrease in
their HRQOL. In boys, a slight increase in HRQOL across all
diagnosis groups was observed. Hence, based on the results
of this study, the positive influence of hGH treatment on
growth (39–41) can now be supplemented by an increase in
HRQOL in this specific patient group, considering the lack
of potential confounders such as comorbidities, socioeconomic
background or social inclusion, which were not assessed within
the study. The finding of a reduction in HRQOL in the untreated
comparison group was unexpected. A possible explanation
for this might be that these children and adolescents are
aware of treatment options for short statured people, such as
hGH treatment, but are unable to get access to this kind of
treatment due to their diagnosis which is not approved for
hGH treatment in Germany. Considering the fact that these
children also contacted pediatric endocrinologists and seeking
for treatment, this might negatively impact on their HRQOL
over time.
Analyzing the parents data, there was also a significant
multivariate main effect of time, but no multivariate main
effects of treatment status or interaction effects between time
and treatment status, were found. Still, it seems important
to us that the univariate analyses for the main effect of
time revealed a significant improvement from baseline to
1-year after start of treatment on the Effects on parents
scale, for both intervention and comparison groups. This is
an important finding since the results from another large
European cross-cultural study allowed us the determination
of caregiving stress as an important risk factor for parent’s
impaired quality of life, as well as its mediating role between
children’s psychosocial functioning and parents’ outcomes (42).
Another study by Brod et al. (43) about treatment burden
described parents not only as substantially impacted by worry
surrounding their children’s treatment administration, but also
by their worry about causing the child pain and medication
costs. This study confirms parental feelings of sadness about
the need for treatment, guilt, and frustration with injection
administration. Taking into account these findings and the
results of this and our former studies, we agree with the
recommendations by Gardner et al. (44), who suggest that
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TABLE 3 | Univariate analyses of covariance of HRQOL changes from baseline and 1-year follow-up between treated (idiopathic growth hormone deficiency and small for
gestational age) and untreated (idiopathic short stature) patients.
Treated with hGH Untreated
Mean (SD) Mean (SD) F p η2p
Patient-reports
Physical T0 48.99 (26.96) 69.91 (18.22) 8.51 <0.01 0.15
T1 62.65 (22.85) 61.94 (27.57)
Social T0 45.67 (26.64) 66.42 (20.42) 14.76 <0.01 0.24
T1 62.04 (25.86) 58.51 (23.70)
Emotional T0 47.06 (24.86) 70.71 (26.56) 11.68 <0.01 0.20
T1 61.24 (23.29) 62.18 (26.80)
Coping T0 60.98 (22.29) 67.78 (21.62) 2.44 0.13 0.05
T1 60.56 (16.19) 57.08 (18.03)
Beliefs T0 41.86 (30.03) 68.06 (31.21) 3.23 0.08 0.06
T1 46.59 (33.88) 56.60 (28.72)
Total score T0 48.88 (24.17) 69.01 (19.50) 9.72 <0.01 0.16
T1 61.60 (22.88) 60.88 (24.20)
Parents-reports
Physical T0 46.78 (25.54) 62.50 (25.90) 0.14 0.71 0.00
T1 54.11 (25.04) 63.92 (26.11)
Social T0 48.20 (24.64) 58.62 (24.46) 0.79 0.38 0.01
T1 55.49 (25.73) 58.50 (27.39)
Emotional T0 47.88 (24.37) 58.19 (23.58) 0.85 0.36 0.01
T1 55.89 (24.63) 60.16 (27.56)
Coping T0 48.30 (17.03) 59.89 (21.49) 1.56 0.22 0.02
T1 50.42 (15.68) 55.18 (24.01)
Beliefs T0 51.92 (28.97) 61.25 (32.23) 0.24 0.62 0.00
T1 50.88 (29.08) 57.19 (36.01)
Future T0 52.05 (30.38) 70.25 (25.31) 3.33 0.07 0.03
T1 59.73 (28.37) 63.56 (29.28)
Effects on parents T0 49.48 (22.10) 59.84 (24.41) 0.25 0.62 0.00
T1 55.62 (21.70) 58.99 (27.36)
Total score T0 50.56 (23.57) 60.97 (22.46) 1.33 0.25 0.01
T1 57.34 (23.31) 60.63 (25.05)
Repeated measures MANCOVA for the QoLISSY scales and a repeated measures ANCOVA for the QoLISSY Total score. Children’s age and time difference between both measurement
points were entered into the models as covariates
Repeated measurement: T0, baseline; T1, 1-year follow-up; IGHD, idiopathic growth hormone deficiency; SGA, small for gestational age; ISS, idiopathic short stature; SD, standard
deviation; F, f-value; p, p-value; η2p , partial eta square.
clinicians must consider factors beyond height when selecting
and preparing patients and parents for treatment. In accordance,
we emphasize the importance of a shared decision-making
paradigm in which clinicians, patients, and their parents make
decisions for and against treatment with hGH, based on the
best available evidence with full knowledge about evolving
scientific controversies.
Limitations and Strength
To our knowledge, this is the first study to examine the effects of
hGH treatment on HRQOL in a longitudinal study design within
a multicenter study in Germany using a short stature specific
HRQOL questionnaire. Nevertheless, our study has several
limitations that should be acknowledged. When interpreting the
results, it should be considered that the sample size between the
groups was uneven. Furthermore, the sample is very selective and
represents a homogeneous group of patients and parents that is
not necessarily representative of the overall target population,
since all of them contacted growth clinics and hence recognized
that short stature may be a problem, that treatment options are
available, and that treatment may be necessary. Moreover, the
selected age groups of this study need to be critically discussed.
Usually, it is uncommon that adolescents aged >13 years old
are treated with hGH because treatment is more effective at
a prepubertal stage and children that are short-statured are
typically diagnosed in early childhood (45). However, in this
study, adolescents aged >13 years were also included in the
sample as patients with a late diagnosis. In light of this limitation,
it needs to be considered that only a developmental delay could be
present. Still, this limitation was unavoidable due to small sample
sizes of the study, and therefore this age group was also included
in the analysis.
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FIGURE 2 | Changes in patient-reported QoLISSY Total score from baseline to 1-year after start of hGH treatment for the intervention group (patients with IGHD and
SGA) and comparison group (untreated patients with ISS). Two-factorial repeated measurement ANCOVA for the QoLISSY Total score. Covariates appearing in the
model were evaluated at the following values: Age at baseline = 10.91 years; Time difference between baseline and 1-year follow-up = 12.74 months.
FIGURE 3 | Changes in parent-reported QoLISSY Total score from baseline to 1-year after start of hGH treatment for the intervention group (patients with IGHD and
SGA) and comparison group (untreated patients with ISS). Two-factorial repeated measurement ANCOVA for the QoLISSY Total score. Covariates appearing in the
model were evaluated at the following values: age at baseline = 7.81 years; Time difference between baseline and 1-year follow-up = 12.45 months.
Besides, the desired treatment duration of 1 year was difficult
to adhere to because the participating families did not show up
exactly 1 year after treatment started in the participating center
where they received the treatment. Hence, the time window from
assessing the HRQOL at baseline to 1-year after start of treatment
differed across participants and was subsequently controlled in
the analyses. Although 1 year of hGH treatment might be too
short to assess long-term effects, this time period is long enough
to detect differences in HRQOL. This effect was also presented
in a recent study by González Briceño et al. (46), who assessed
HRQOL with the QoLISSY questionnaire before and after 1 year
of growth hormone treatment in French children≥4 years.
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Another important limitation is that due to organizational
issues, we were not able to include a normal stature, age-matched
control group of children or a group of untreated children
with IGHD or SGA for comparison. Our study was, however,
conducted in a hospital/clinical practice setting and hence
provides real world insight into the effects of hGH treatment on
HRQOL in children with IGHD and SGA. Furthermore, some
participants, especially patients diagnosed with ISS, which served
as a comparison group, were already near normal height (see
Table 1). Besides, comparing children who received treatment
to children who received no treatment due to drug regulation
might also evoke frustration in children (i.e., children with
ISS) who are short, but are not able to receive treatment. This
might explain, why children with ISS report a decrease in
their HRQOL.
Nevertheless, our study included a larger number of children
compared with previous studies that have examined the effects
of hGH treatment on the quality of life in children with
IGHD and SGA (27, 47, 48). In addition, our study used
the cross-culturally validated short stature specific QoLISSY
questionnaire, which takes into consideration both the child’s
and parents’ perspectives. The use of such a questionnaire
is of great value since both reports provide important
information from two sources (child vs. parent as proxy) that
have already been shown to report different quality of life
outcomes (49).
CONCLUSIONS
Our results showed that improving growth of short children
by hGH treatment can also affect their short-term HRQOL
and might prevent possible psychological consequences of
short stature. This information might help to optimize
health care in this patient group and to design more
individualized care in order to fulfill the needs of patients
and parents. Applying the QoLISSY questionnaire in medical
practice helped to bring a better understanding of the
HRQOL of children and adolescents diagnosed with IGHD,
SGA, or ISS.
Although our findings demonstrate that hGH treatment
can improve the HRQOL of German children with IGHD or
SGA a further follow-up study is warranted to ascertain the
long-term effects and the mechanisms through which hGH
treatment improves the patients’ HRQOL. The elucidation
of factors that modify the relationship between hGH
therapy and HRQOL are required to adequately determine
which patients will derive the most benefit from hGH
treatment and to more efficiently allocate health resources
and policies.
Access to the QoLISSY Questionnaire
QoLISSY is a joint initiative between Pfizer Limited and the
University Medical Center Hamburg–Eppendorf. Copyright
Pfizer Limited all rights reserved. The European QoLISSY
instrument, together with comprehensive information of
its development and validation process is published in
the QoLISSY’s User’s Manual (31). The Manual, which
is available upon request, includes QoLISSY child and
parent forms, as well as scoring information (http://www.
pfizerpatientreportedoutcomes.com/therapeutic-areas/cv-
metabolic/endocrine).
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